IRS Wants Feedback on Tax Cheat Penalty Forms
Published Date: 9/2/2026
Notice
Summary
In accordance with the Paperwork Reduction Act of 1995, the IRS is inviting comments on the information collection request outlined in this notice.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Tax Preparer Recordkeeping Requirement
If you are a tax return preparer, these rules require you to record your name, taxpayer identification number, and principal place of work; make each return or refund claim you prepare available for inspection by the Commissioner; and document that you advised the taxpayer of the penalty standards applicable to avoid penalties under section 6694 (per sections 6060, 6107, and 6694). The IRS estimates this collection covers 127,800,734 respondents, takes about 5 minutes per response, and totals 10,224,059 annual burden hours.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17622, Federal Independent Dispute Resolution Operations; Correction
This document corrects typographical errors and omissions in the final rule that appeared in the June 4, 2026, Federal Register titled "Federal Independent Dispute Resolution Operations" (referred to hereafter as the "IDR final rule"). The effective date of the IDR final rule was August 3, 2026.
2026-11343, Trump Accounts; Hearing
The IRS is holding a public hearing on July 16, 2026, about new rules for opening Trump accounts. People interested in speaking must submit their topics by June 15, or the hearing gets canceled. These changes could affect how certain accounts are managed and reported, so stay tuned for updates that might impact your money and taxes.
2026-11140, Federal Independent Dispute Resolution Operations
Starting soon, health plans and insurers must share clearer info when they pay or deny surprise medical bills. They’ll use special codes to explain these decisions, especially when dealing with folks they don’t have contracts with. This helps patients and providers understand bills better and speeds up fixing disputes, with no extra costs for most people.
2026-09141, Section 45Z Clean Fuel Production Credit; Hearing
The IRS is holding a telephonic-only public hearing from May 27-29, 2026, about new rules for clean fuel production credits. These rules explain who can get credits, how to measure emissions, and how to register. If you’re involved in clean fuel, this could affect your money and how you apply for credits.
2026-08344, Section 45Z Clean Fuel Production Credit; Hearing
The IRS is holding a public hearing in late May 2026 to talk about new rules for the Clean Fuel Production Credit. These rules will explain who can get the credit, how to measure emissions, and what paperwork is needed. If you make clean fuel, these changes could affect your tax credits and when you can claim them.
2026-07085, Excise Tax on Remittance Transfers
Starting January 1, 2026, certain companies and people who send money transfers to others will face a new excise tax. The IRS is proposing clear rules on who pays this tax and how it works, so everyone knows what to expect. If you’re involved, get ready to follow these new rules and share your thoughts by June 12, 2026!
Previous / Next Documents
Previous: 2026-17965, Foreign-Trade Zone 27; Application for Subzone; Persimmon Technologies Corporation; Bedford, Massachusetts
Next: 2026-17968, Determination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that CARAFATE (sucralfate) oral suspension, 1 gram (g)/10 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.